Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Change in Receivables readings, the most recent being $1.6 million for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 50.28% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $775000.0, a 270.33% increase, with the full-year FY2025 number at $236000.0, up 111.99% from a year prior.
  • Change in Receivables hit $1.6 million in Q4 2025 for Enanta Pharmaceuticals, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $4.1 million in Q4 2021 to a low of -$11.6 million in Q1 2021.
  • Median Change in Receivables over the past 5 years was $591500.0 (2022), compared with a mean of -$1.2 million.
  • Biggest five-year swings in Change in Receivables: plummeted 1325.03% in 2023 and later skyrocketed 343.08% in 2024.
  • Enanta Pharmaceuticals' Change in Receivables stood at $4.1 million in 2021, then crashed by 44.33% to $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then soared by 343.08% to $1.1 million in 2024, then soared by 50.28% to $1.6 million in 2025.
  • The last three reported values for Change in Receivables were $1.6 million (Q4 2025), -$1.5 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.